Merck & Co. Inc. (MRK) News
Filter MRK News Items
MRK News Results
|Loading, please wait...|
MRK News Highlights
- MRK's 30 day story count now stands at 22.
- Over the past 16 days, the trend for MRK's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- LI, LUNG and VTRS are the most mentioned tickers in articles about MRK.
Latest MRK News From Around the Web
Below are the latest news stories about MERCK & CO INC that investors may wish to consider to help them evaluate MRK as an investment opportunity.
Amplifying the Power of Women in Chemistry
Merck & Co., Inc.
The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton
Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton are part of the Zacks top Analyst Blog.
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Merck (MRK) closed at $105.54, marking a -0.29% move from the previous day.
Top Research Reports for Merck, Intel & MercadoLibre
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Intel Corporation (INTC) and MercadoLibre, Inc. (MELI).
Merck, Viatris settle patent dispute over Januvia
7 Defensive Stocks to Buy During This Chaotic Spell
With turmoil erupting on Wall Street over the banking sector crisis, investors should turn to reliable defensive stocks to buy.
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Merck's (MRK) Co-formulation Therapy Fails Lung Cancer Study
Data from a mid-stage study showed that Merck's (MRK) MK-7684A did not improve progression-free survival as a potential treatment for patients with metastatic non-small cell lung cancer.
Merck's Keytruda Combo Therapy Less Effective Than Chemo In Lung Cancer Patients, Data Shows
https://cdn.benzinga.com/files/images/story/2023/03/17/mrk.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Merck & Co Inc's (NYSE: MRK) MK-7684A failed the open-label portion of a Phase 2 study KeyVibe-002 trial. MK-7684A, a combination of Keytruda (pembrolizumab) and in-house anti-TIGIT compound vibostolimab, did not improve patients' progression-free survival compared to chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with progressive disease after treatment wit